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Editorial
Perspectives on the Endocrine Society Clinical Practice
Guideline for the Evaluation and Treatment of Women
with Hirsutism
A Clinical Practice Guideline for the evaluation and treat-
ment of women with hirsutism was recently published
by The Endocrine Society [1]. The topic was considered
a Society priority and, similar to the case with the So-
ciety’s previous guidelines, the process began with the
selection of experts in pediatric, medical, and gyneco-
logical endocrinology, dermatology, and metanalysis
methodology to serve on the task force. The charge was
to draft a guideline based upon review of the best ava-
ilable evidence and to grade the evidence by objective
criteria. The resulting document went through
a multi-staged revision and review process that inclu-
ded the opportunity for member input prior to submis-
sion for peer-review.
As a member of the task force, I can vouch that the
process of evaluating the evidence on which to base gu-
idelines was not easy. Consistent results from well-con-
trolled, randomized, double-blinded studies were too
few to permit strong recommendations. Consequently,
the document makes “suggestions” that warrant care-
ful consideration of each patient’s preferences, after
considering the access to and affordability of diagno-
stic and therapeutic alternatives.
The target audience for these guidelines was practi-
cing general endocrinologists, with the expectation that
non-endocrinologists would consult these guidelines,
as well. Accordingly, the guidelines were written with
an eye to the diagnostic and therapeutic tools that are
generally available to the majority of practitioners. Thus
they represent a minimalist approach and do not prec-
lude a more aggressive diagnostic or therapeutic ap-
proach according to individual patient and practice si-
tuations.
To endocrinologists, hirsutism, excess sexual hair
growth, is more than a cosmetic problem: it is a sign of
risk for a hyperandrogenic state. Hyperandrogenism,
in turn, has potential serious implications that include
infertility, malignancy, and diabetes mellitus and dysli-
pidemia, with their cardiovascular disease risk.
Testosterone is the major circulating hormone that
determines androgenization. However, its measure-
ment poses a major problem for practitioners because
the state of generally available plasma total testostero-
ne assays is so poor. There are many pitfalls in testoste-
rone assays at the low blood levels of women. The au-
tomated assays that are used in many laboratories are
often not suitable to measure women’s levels accurate-
ly. Systematic differences between assays and excessi-
vely broad normal ranges derived from populations of
apparently normal women with unrecognized andro-
gen excess further complicate the interpretation of testo-
sterone results provided by many laboratories.
The plasma-free testosterone concentration is abo-
ut 50% more sensitive for the detection of hyperandro-
genemia than the total testosterone concentration. This
is because hirsute women commonly have a relatively
low level of sex hormone-binding globulin (SHBG),
which is the main determinant of the bioactive portion
of plasma testosterone, the fraction that is free or “bio-
available” (which includes that loosely bound to albu-
min). However, assaying the free or bioavailable testo-
sterone level introduces other potential sources of er-
ror. The best methods calculate them as the product of
the total testosterone and a function of SHBG. Direct
assays of the free testosterone concentration are to be
avoided. The most accurate androgen determinations
are provided by specialty laboratories using established
validated assays. Plasma total and free testosterone are
best assessed in the early morning, on days 4–10 of the
menstrual cycle in regularly cycling women, the time
for which norms are standardized.
Because reliable testosterone assays are not availa-
ble to many physicians, the task force suggested a work-
up only in hirsute patients at high-risk for hyperandro-
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genemia. Risk factor assessment includes not only the
degree of hirsutism, but the evaluation of symptoms
and signs for risk of serious underlying causes of hype-
randrogenism. A plasma total testosterone level was
suggested as the preferred primary test for hyperan-
drogenemia. This suggestion places a relatively high
value on the identification of treatable underlying di-
seases. The suggestion of not testing for testosterone
elevation in low-risk patients (isolated mild hirsutism)
places a relatively high value on avoiding the risk of
false positives, with the resulting increase in unneces-
sary medical tests and procedures. It places a relatively
low value on the potential benefits of early detection of
mild hyperandrogenemia that will not affect initial
management and outcome. Plasma-free testosterone is
the single most useful test to detect hyperandrogene-
mia when the clinical picture is discordant with the to-
tal testosterone level. Indeed, if a reliable method for
measuring plasma-free or bioavailable testosterone is
available to the practitioner, cost is not an issue, and it
would facilitate patient management, it would be
a more reasonable choice for initial testing.
To patients, excess sexual hair has different conno-
tations than it does to endocrinologists, and the task
force recommendations for treatment take this into ac-
count. To the concerned patient, unwanted hair is
a symptom that affects quality of life and requires treat-
ment. The degree of hirsutism bears no necessary rela-
tionship to the distress it causes the patient. Some can-
not tolerate a degree of superfluous hair growth that is
within normal limits, i.e., not true hirsutism —“even
a single hair casts its shadow” [2] — while others are
accepting of substantially abnormal degrees of sexual hair
growth. Consequently, the suggestion is made to under-
take pharmacological or direct hair removal methods in
women who, despite cosmetic measures, have sexual hair
in amounts bothersome to them, no matter how mild.
The greatest conundrum faced by the task force in
evaluating the evidence for pharmacotherapy was the
discrepancy between our collective personal experien-
ce and the results of metanalyses of controlled trials
comparing the relative efficacy of estrogen-progestin
oral contraceptive pills (OCPs) and antiandrogens in
hirsutism. Our systematic review identified only one
placebo-controlled, randomized trial and a second trial
that compared OCPs to no therapy. Both trials had im-
portant methodological and reporting limitations, so the
evidence was of very low quality. However, a combi-
ned analysis of these trials indicated that OCP therapy
was associated with a significant reduction in hirsutism
scores, which was of a degree comparable to that
found in several trials of antiandrogen monotherapy.
Only a small, though significant, benefit was found in
controlled studies of OCP-antiandrogen combination
therapy vs. monotherapy with a non-antiandrogenic
OCP. This contrasts with convincing evidence from
observational studies of a reduction of about one third
in fully virile sexual hair growth with combination an-
tiandrogen-OCP therapy [3]. We concluded by
suggesting adding an antiandrogen if patient-important
hirsutism remains despite six or more months of OCP
monotherapy.
Finally, it is worth noting that the task force found
little evidence for a substantial benefit of insulin-low-
ering drugs to hirsutism per se. Therefore, while insu-
lin-lowering therapies may improve ovulatory efficien-
cy and are important for treatment of the metabolic di-
sturbances that often are associated with hyperandrogen-
emia, they cannot be used as monotherapy with the
expectation that they will significantly alleviate hirsutism.
It is hoped that this overview will help practitioners
to place the new guideline for the evaluation and treat-
ment of hirsutism in the perspective of their practice
situation.
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